Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sotorasib

FDA-approved product (tablet, oral), marketed as Lumakras.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Sotorasib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis71.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sotorasib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sotorasib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

    NCT07012031 · start 2026-06-17

    Registered record
    Registry ID
    NCT07012031
    Conditions
    Locally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
    Interventions
    Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Sotorasib; Trastuzumab Deruxtecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-06-17
    Completion
    2027-06-14
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
    InterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test +4 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

    NCT07318389 · start 2026-06-10

    Registered record
    Registry ID
    NCT07318389
    Conditions
    Dynamic Tumor Resistance; Metastatic Colorectal Cancer
    Interventions
    SOC (Standard of care); Bevacizumab; Cetuximab; Panitumumab; FOLFIRI; FOLFOX; Encorafenib; Adagrasib; Trifluridine/tipiracil (TAS-102); Trastuzumab deruxtecan; Tucatinib; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-06-10
    Completion
    2029-11-14
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDynamic Tumor Resistance; Metastatic Colorectal Cancer
    InterventionSOC (Standard of care); Bevacizumab; Cetuximab; Panitumumab +8 more
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

    NCT07172919 · start 2026-01-02

    Registered record
    Registry ID
    NCT07172919
    Conditions
    Advanced Solid Tumors
    Interventions
    Sotorasib; Panitumumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-02
    Completion
    2028-07-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionSotorasib; Panitumumab
    PhasePhase 2
    Registry statusRecruiting

  • 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

    NCT07124884 · start 2025-08-31

    Registered record
    Registry ID
    NCT07124884
    Conditions
    Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer
    Interventions
    Administration of experimental treatment association (sotorasib, panitumumab 5FU)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-08-31
    Completion
    2030-12-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer
    InterventionAdministration of experimental treatment association (sotorasib, panitumumab 5FU)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

    NCT07143513 · start 2025-08-11

    Registered record
    Registry ID
    NCT07143513
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Sotorasib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-08-11
    Completion
    2025-12-07
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionSotorasib
    PhaseNot recorded
    Registry statusCompleted

  • AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC

    NCT06068153 · start 2025-03

    Registered record
    Registry ID
    NCT06068153
    Conditions
    Metastatic Non Small Cell Lung Cancer; KRAS G12C
    Interventions
    Sotorasib; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2025-03
    Completion
    2026-12-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Non Small Cell Lung Cancer; KRAS G12C
    InterventionSotorasib; Lenvatinib
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of Sotorasib in People With Brain Tumors

    NCT06807619 · start 2025-01-29

    Registered record
    Registry ID
    NCT06807619
    Conditions
    Brain Tumor
    Interventions
    Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-01-29
    Completion
    2028-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Tumor
    InterventionSotorasib
    PhasePhase 1
    Registry statusRecruiting

  • A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

    NCT06497556 · start 2024-09-23

    Registered record
    Registry ID
    NCT06497556
    Conditions
    Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
    Interventions
    Divarasib; Sotorasib; Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-09-23
    Completion
    2029-11-30
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; KRAS G12C Lung Cancer
    InterventionDivarasib; Sotorasib; Adagrasib
    PhasePhase 3
    Registry statusActive not recruiting

  • ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

    NCT06532149 · start 2024-08-05

    Registered record
    Registry ID
    NCT06532149
    Conditions
    NSCLC Stage IV; Sex Disorder; Hypogonadism, Male; Erectile Dysfunction
    Interventions
    Alectinib; Brigatinib; Lorlatinib 100 mg; Osimertinib; Sotorasib; Dabrafenib; Trametinib; Selpercatinib; Pembrolizumab; Cemiplimab; Nivolumab; Carboplatin; Pemetrexed; Paclitaxel
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-08-05
    Completion
    2026-09-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC Stage IV; Sex Disorder; Hypogonadism, Male; Erectile Dysfunction
    InterventionAlectinib; Brigatinib; Lorlatinib 100 mg; Osimertinib +10 more
    PhaseNot recorded
    Registry statusRecruiting

  • Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

    NCT06252649 · start 2024-07-17

    Registered record
    Registry ID
    NCT06252649
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    FOLFIRI Regimen; Sotorasib; Panitumumab; Bevacizumab-awwb
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-07-17
    Completion
    2032-04-25
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionFOLFIRI Regimen; Sotorasib; Panitumumab; Bevacizumab-awwb
    PhasePhase 3
    Registry statusRecruiting

  • A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants

    NCT06061523 · start 2024-07-15

    Registered record
    Registry ID
    NCT06061523
    Conditions
    Healthy Participants
    Interventions
    Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2024-07-15
    Completion
    2024-09-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionSotorasib
    PhasePhase 1
    Registry statusWithdrawn

  • DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

    NCT06645236 · start 2023-12-22

    Registered record
    Registry ID
    NCT06645236
    Conditions
    Metastatic Colorectal Cancer (mCRC)
    Interventions
    therascreen® KRAS RGQ PCR Kit
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-12-22
    Completion
    2030-10-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer (mCRC)
    Interventiontherascreen® KRAS RGQ PCR Kit
    PhaseNot applicable
    Registry statusRecruiting

  • A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    NCT05920356 · start 2023-11-16

    Registered record
    Registry ID
    NCT05920356
    Conditions
    Non-Small Cell Lung Cancer (NSCLC)
    Interventions
    Sotorasib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-11-16
    Completion
    2032-06-29
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer (NSCLC)
    InterventionSotorasib; Pembrolizumab
    PhasePhase 3
    Registry statusRecruiting

  • Rivaroxaban Sotorasib Interaction Study

    NCT06314763 · start 2023-11-09

    Registered record
    Registry ID
    NCT06314763
    Conditions
    Drug Drug Interaction Study
    Interventions
    Rivaroxaban 20mg; Sotorasib 960mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-11-09
    Completion
    2024-03-21
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction Study
    InterventionRivaroxaban 20mg; Sotorasib 960mg
    PhasePhase 4
    Registry statusCompleted

  • K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation

    NCT06127940 · start 2023-10-15

    Registered record
    Registry ID
    NCT06127940
    Conditions
    Non-small Cell Lung Cancer Metastatic
    Interventions
    Stereotactic body radiation therapy (SBRT); Temporary Stopping
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2023-10-15
    Completion
    2026-01-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Metastatic
    InterventionStereotactic body radiation therapy (SBRT); Temporary Stopping
    PhasePhase 1
    Registry statusUnknown